

# Appendixes

## Appendix 1: 2007–08 data elements

The detailed data definitions for the data elements included in the AODTS–NMDS for 2007–08 are published in the National health data dictionary (NHDD), version 13 (HDSC 2006) and are available on the AIHW’s Metadata Online Registry (METeOR) at <meteor.aihw.gov.au/content/index.phtml/itemId/334288>. Table A1.1 lists all data elements collected for 2007–08.

**Table A1.1: Data elements for the AODTS–NMDS, 2007–08**

Data element	METeOR identifier
<b>Establishment-level data elements</b>	
Establishment identifier (comprising)	269973
– state identifier	269941
– establishment sector	269977
– region code	269940
– establishment number	269975
Geographical location of establishment	341802
<b>Client-level data elements</b>	
Client type	270083
Country of birth	270277
Date of birth	287007
Date of cessation of treatment episode for alcohol and other drugs	270067
Date of commencement of treatment episode for alcohol and other drugs	270069
Establishment identifier	269973
Indigenous status	291036
Injecting drug use	270113
Main treatment type for alcohol and other drugs	270056
Method of use for principal drug of concern	270111
Other drugs of concern	270110
Other treatment type for alcohol and other drugs	270076
Person identifier	290046
Preferred language	304128
Principal drug of concern	270109
Reason for cessation of treatment episode for alcohol and other drugs	270011
Sex	287316
Source of referral to alcohol and other drug treatment services	269946
Treatment delivery setting for alcohol and other drugs	270068
<b>Supporting items</b>	
Cessation of treatment episode for alcohol and other drugs	327302
Commencement of treatment episode for alcohol and other drugs	327216
Treatment episode for alcohol and other drugs	268961
Service delivery outlet	268970

## **Appendix 2: Policy and administrative features in each jurisdiction**

### **New South Wales**

New South Wales Health collects data from all Australian Government/state government-funded agencies as part of requirements stipulated in a signed service agreement at the start/renewal of each funding agreement. Data are provided monthly by agencies to their respective Area Health Service (AHS) Drug and Alcohol Data Coordinator (DADC) on treatment episodes currently open and those closed in the preceding month. The AHS DADC is responsible for checking and cleaning the data and forwarding it to the Mental Health and Drug and Alcohol Office at New South Wales Health. Frequency and data-quality reports are provided by New South Wales Health to AHS and by AHS DADCs to agencies every 6 months detailing services in the previous 6 or 12 months. New South Wales Health forwards cleaned data on treatment episodes closed during the reporting period to the AIHW annually.

New South Wales Health has developed a statewide data collection system in Microsoft Access<sup>®</sup>, called MATISSE, which is provided free of charge to agencies to enable the registration of clients and the collection of the New South Wales MDS and the AODTS-NMDS. This data collection system will gradually be replaced in public sector agencies as the Community Health Information Management Enterprise is rolled out across New South Wales.

### **Victoria**

The Victorian Drug Treatment Service Program provides a range of services to cover the needs of clients experiencing substance abuse issues. The Victorian Government purchases these drug treatment services from independent agencies (non-government organisations) on behalf of the community, and has developed the concept of an 'episode of care' as the fundamental unit for service funding. An episode of care is defined as 'a completed course of treatment, undertaken by a client under the care of an alcohol and drug worker, which achieves significant agreed treatment goals'.

The episode of care is a measure of successful client outcomes. It aims to develop performance measurement beyond activities, throughputs and outputs, to measure what the client gets out of treatment. Agencies funded to provide drug treatment services in Victoria have service provision targets, which are defined in terms of number of episodes of care to be provided by service type and by target group (for example, youth or adult). As a requirement of their funding agreement with the Victorian Department of Human Services, agencies are required to submit data on a quarterly basis detailing their provision of drug treatment services and achievement of episodes of care. A subset of this data is contributed to the AODTS-NMDS annually.

The majority of Victorian AODT service providers use the SWITCH or FullADIS information systems to report quarterly activity. Both are ageing systems that are being replaced in hospitals and community health centres by HealthSMART client management systems

known as CMS and PCMS. Some AODTS agencies began migration to HealthSMART systems in 2007–08.

## **Queensland**

Queensland Health collects data from all Queensland Government AODT service providers and from all Queensland Illicit Drug Diversion Initiative – Police and Court Diversion clients. The Australian Government currently collects data from the Australian Government-funded agencies operating in Queensland.

Queensland Health has a statewide web-based clinical information management system supporting the collection of AODTS-NMDS items for all Queensland Government AODT services.

## **Western Australia**

Data are provided by both government and non-government sectors. Non-government services are contracted by the Drug and Alcohol Office (DAO) to provide alcohol and drug services. They have contractual obligations to incorporate the data elements of the AODTS-NMDS in their collections. They are also obliged to provide data in a regular and timely manner to DAO. These data are collated and checked by DAO before submission to the AIHW annually.

## **South Australia**

Data are provided by government (Drug and Alcohol Services SA – DASSA) and non-government alcohol and other drug treatment services.

Non-government alcohol and other drug treatment services in South Australia are subject to service agreements with the South Australian Minister for Mental Health and Substance Abuse. As part of these service agreements, non-government organisations are required to provide timely client data in accordance with the AODTS-NMDS guidelines. Data are forwarded to DASSA for collation and checking. DASSA then forwards cleaned data to the AIHW annually. DASSA does not collect information directly from those services funded by the NGOTGP. These data are provided directly to the Australian Government Department of Health and Ageing.

## **Tasmania**

All Tasmanian-funded alcohol and other drug treatment agencies sign a service agreement at the start of funding each financial year. A key element of the agreement is a requirement to input AODTS-NMDS data into the current collection application, as well as report against specific performance indicators in their annual reports to the Department of Health and Human Services.

## **Australian Capital Territory**

ACT service providers supply ACT Health with data for the NMDS at the end of the financial year, as specified in their Service Funding Agreement. In the past, service providers used a range of systems to collect their data, but since 1 July 2007 the service providers have been encouraged to use a standardised reporting system developed by ACT Health to enhance uniformity and reliability of data.

## **Northern Territory**

Alcohol and other drug treatment services in the Northern Territory are provided by government and non-government agencies. The bulk of services provided through non-government agencies are funded via service-level agreements with the NT Department of Health and Families. All funded agencies are required to provide the AODTS-NMDS data items to the department on a regular and timely basis. Summary statistical reports are sent to all agencies every 6 months detailing client activity for the previous 12 months.

The department has recently implemented an intranet-based data entry system for NMDS data collection and is now working on developing this into a web-based system for use by non-government organisations.

## **Australian Government Department of Health and Ageing**

The Australian Government Department of Health and Ageing funds a number of alcohol and other drug treatment services under the National Illicit Drug Strategy Non-Government Organisation Treatment Grants Program (NGOTGP). These agencies are required to collect data (according to the AODTS-NMDS specifications) to facilitate the monitoring of their activities and to provide quantitative information to the Australian Government on their activities. Data from these agencies are generally submitted to the relevant state/territory health authority, except for a number of agencies in Western Australia, South Australia and Queensland which submit data annually to the Department of Health and Ageing.

Reported numbers for each state/territory in the AODTS-NMDS report include services provided under the National Illicit Drug Strategy NGOTGP.

## Appendix 3: Detailed tables

### Client profile table

Table A3.1: Client data items by jurisdiction, 2007–08

Client item	NSW	Vic <sup>(a)</sup>	Qld <sup>(b)</sup>	WA	SA	Tas <sup>(c)</sup>	ACT	NT	Australia
<b>Client type</b>									
Own drug use	41,277	45,104	26,332	17,014	8,712	2,124	3,662	3,496	147,721
Others' drug use	801	2,434	563	1,691	318	178	76	216	6,277
<b>Sex</b>									
Male	28,263	30,803	18,802	11,710	6,204	1,577	2,478	2,315	102,152
Female	13,809	16,617	8,090	6,994	2,822	725	1,260	1,385	51,702
Not stated	6	118	3	1	4	—	—	12	144
<b>Age group (years)</b>									
10–19	2,471	6,741	4,379	2,244	504	385	519	375	17,618
20–29	11,894	14,830	9,481	6,033	2,489	811	1,222	1,176	47,936
30–39	13,076	13,115	6,759	5,474	2,886	579	978	1,140	44,007
40–49	8,860	8,241	3,973	3,053	1,933	333	670	659	27,722
50–59	4,042	3,255	1,611	1,378	877	134	250	241	11,788
60+	1,732	1,106	612	471	327	57	91	44	4,440
Not stated	3	250	80	52	14	3	8	77	487
<b>Indigenous status</b>									
Indigenous	4,185	2,734	3,121	2,811	617	250	400	2,322	16,440
Non-Indigenous	36,704	41,168	22,249	15,614	8,025	1,877	3,054	1,324	130,015
Not stated	1,189	3,636	1,525	280	388	175	284	66	7,543
<b>Country of birth</b>									
Australia	36,641	40,816	23,355	15,548	7,854	2,216	3,297	3,357	133,084
England	1,039	626	506	1,162	396	19	79	10	3,837
Germany	105	97	89	62	38	2	5	5	403
Ireland	143	109	60	107	29	3	11	—	462
Italy	60	110	28	43	27	3	5	—	276
New Zealand	804	794	1,186	520	91	13	58	41	3,507
Scotland	165	139	113	182	65	7	24	4	699
South Africa	99	62	67	88	13	3	5	1	338
United States of America	117	106	56	72	9	1	7	2	370
Viet Nam	225	451	58	46	69	—	9	10	868
All other countries	1,985	2,704	926	846	340	33	194	27	7,055
Inadequately described	6	—	92	—	—	1	2	—	1,625
Not stated	689	1,524	359	29	99	1	42	255	1,474

(continued)

**Table A3.1 (continued): Client data items by jurisdiction, 2007–08**

Client item	NSW	Vic <sup>(a)</sup>	Qld <sup>(b)</sup>	WA	SA	Tas <sup>(c)</sup>	ACT	NT	Australia
<b>Preferred language</b>									
Arabic	45	86	2	3	3	—	1	—	140
Australian Indigenous languages	17	33	25	89	2	—	3	1,004	1,173
Croatian	14	8	2	1	5	—	1	—	31
English	41,107	45,140	26,468	18,518	8,815	2,301	3,667	2,343	148,359
Greek	22	21	—	—	6	—	1	—	50
Italian	19	16	7	4	8	—	2	—	56
Serbian	13	12	2	1	1	—	—	—	29
Spanish	57	41	13	5	6	—	3	—	125
Turkish	11	23	3	2	—	—	—	1	40
Vietnamese	117	258	14	11	38	—	3	—	441
All other languages	199	326	110	51	43	1	15	13	758
Inadequately described	7	—	11	—	1	—	1	—	1,594
Not stated	450	1,574	238	20	102	—	41	351	1,202
<b>Source of referral</b>									
Self	16,159	16,951	7,389	7,075	2,953	1,051	2,221	1,608	55,407
Family member/ friend	2,090	1,412	955	1,571	399	60	119	134	6,740
Medical practitioner	5,169	2,100	818	955	441	63	24	87	9,657
Hospital	2,274	649	1,751	378	1,132	21	8	64	6,277
Mental health care service	1,615	955	797	423	156	36	58	57	4,097
AODTS	4,847	6,060	887	1,075	697	72	285	331	14,254
Other community/health care services	888	2,446	495	655	264	96	107	342	5,293
Correctional service	2,974	6,249	2,396	2,398	251	81	140	413	14,902
Police diversion	81	1,073	6,016	329	540	645	99	50	8,833
Court diversion	3,373	1,386	4,037	2,732	301	133	329	343	12,634
Other	2,524	7,879	1,263	1,113	1,665	43	329	176	14,992
Not stated	84	378	91	1	231	1	19	107	912
<b>Total</b>	<b>42,078</b>	<b>47,538</b>	<b>26,895</b>	<b>18,705</b>	<b>9,030</b>	<b>2,302</b>	<b>3,738</b>	<b>3,712</b>	<b>153,998</b>

(a) Victoria's data collection system does not distinguish between 'not stated' and 'inadequately described'.

(b) The total number of closed treatment episodes for Queensland may be under-counted because of the exclusion of a number of non-government agencies.

(c) The total number of closed treatment episodes for Tasmania may be under-counted because two agencies supplied drug diversion data only.

Table A3.2: Client data items by geographical location, 2007–08

Data item	Major cities	Inner regional	Outer regional	Remote	Very remote	Australia
						(number)
<b>Agency sector<sup>(a)</sup></b>						
Government	51,444	13,770	7,440	1,433	202	74,289
Non-government <sup>(b)</sup>	57,291	14,533	5,956	1,428	501	79,709
<b>Total episodes</b>	<b>108,735</b>	<b>28,303</b>	<b>13,396</b>	<b>2,861</b>	<b>703</b>	<b>153,998</b>
						(per cent)
Government	47.3	48.7	55.5	50.1	28.7	48.2
Non-government	52.7	51.3	44.5	49.9	71.3	51.8
<b>Total</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
						(number)
<b>Sex</b>						
Male	72,375	18,826	8,674	1,857	420	102,152
Female	36,272	9,433	4,718	1,002	277	51,702
Not stated	88	44	4	2	6	144
<b>Total episodes</b>	<b>108,735</b>	<b>28,303</b>	<b>13,396</b>	<b>2,861</b>	<b>703</b>	<b>153,998</b>
						(per cent)
Male	66.6	66.5	64.8	64.9	59.7	66.3
Female	33.4	33.3	35.2	35.0	39.4	33.6
Not stated	0.1	0.2	<0.1	0.1	0.9	0.1
<b>Total</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
						(number)
<b>Age group (years)</b>						
10–19	11,071	3,571	2,518	410	48	17,618
20–29	34,355	8,683	3,792	845	261	47,936
30–39	31,742	7,849	3,449	775	192	44,007
40–49	19,775	5,048	2,262	498	139	27,722
50–59	8,417	2,251	916	152	52	11,788
60+	3,159	797	399	74	11	4,440
Not stated	216	104	60	107	—	487
<b>Total episodes</b>	<b>108,735</b>	<b>28,303</b>	<b>13,396</b>	<b>2,861</b>	<b>703</b>	<b>153,998</b>

(continued)

Table A3.2 (continued): Client data items by geographical location, 2007–08

Client Item	Major cities	Inner regional	Outer regional	Remote	Very remote	Australia
(per cent)						
<b>Age group (years)</b>						
10–19	10.2	12.6	18.8	14.3	6.8	11.4
20–29	31.6	30.7	28.3	29.5	37.1	31.1
30–39	29.2	27.7	25.7	27.1	27.3	28.6
40–49	18.2	17.8	16.9	17.4	19.8	18.0
50–59	7.7	8.0	6.8	5.3	7.4	7.7
60+	2.9	2.8	3.0	2.6	1.6	2.9
Not stated	0.2	0.4	0.4	3.7	—	0.3
<b>Total</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
(number)						
<b>Indigenous status</b>						
Indigenous	7,007	3,525	3,395	1,875	638	16,440
Not Indigenous	96,042	23,447	9,588	876	62	130,015
Not stated	5,686	1,331	413	110	3	7,543
<b>Total episodes</b>	<b>108,735</b>	<b>28,303</b>	<b>13,396</b>	<b>2,861</b>	<b>703</b>	<b>153,998</b>
(per cent)						
Indigenous	6.4	12.5	25.3	65.5	90.8	10.7
Not Indigenous	88.3	82.8	71.6	30.6	8.8	84.4
Not stated	5.2	4.7	3.1	3.8	0.4	4.9
<b>Total</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>

(a) Total treatment episodes provided in public (government) and private (non-government) sectors. Agencies funded by the Australian Government Department of Health and Ageing under the Non-Government Organisation Treatment Grants Program are included in the government sector.

(b) Includes only those non-government agencies that received public funding.



## Drugs of concern tables

Table A3.3: Drug-related data items<sup>(a)</sup> by jurisdiction, 2007–08

Drug-related data item	NSW	Vic	Qld <sup>(b)</sup>	WA	SA	Tas <sup>(c)</sup>	ACT	NT	Australia
<b>Injecting drug use</b>									
Current injector	9,594	7,493	3,520	4,915	2,097	237	903	366	29,125
Injected 3–12 months ago	2,153	5,068	1,140	1,250	567	90	280	55	10,603
Injected 12+ months ago	4,640	5,030	2,769	1,809	1,069	171	321	180	15,989
Never injected	21,919	20,436	14,136	7,767	4,495	1,279	1,644	2,465	74,141
Not stated	2,971	7,077	4,767	1,273	484	347	514	430	17,863
<b>Method of use</b>									
Ingests	23,377	23,249	10,703	8,324	5,603	811	2,005	2,652	76,724
Smokes	8,765	9,400	11,196	3,409	1,166	916	601	355	35,808
Injects	8,332	8,999	3,189	4,980	1,772	212	951	321	28,756
Sniffs (powder)	235	357	76	115	30	6	16	13	848
Inhales (vapour)	59	1,810	238	113	8	4	24	127	2,383
Other	81	349	52	36	—	8	42	6	574
Not stated	428	940	878	37	133	167	23	22	2,628
<b>Principal drug of concern</b>									
Analgesics									
Heroin	4,942	6,589	1,089	1,408	778	6	717	42	15,571
Methadone	1,023	468	196	391	129	24	51	14	2,296
Balance of analgesics	1,313	380	834	827	513	120	100	280	4,367
<i>Total analgesics</i>	<i>7,278</i>	<i>7,437</i>	<i>2,119</i>	<i>2,626</i>	<i>1,420</i>	<i>150</i>	<i>868</i>	<i>336</i>	<i>22,234</i>
Sedatives and hypnotics									
Alcohol	20,338	19,928	8,903	6,906	4,598	681	1,792	2,556	65,702
Benzodiazepines	838	926	273	198	175	28	28	21	2,487
Balance of sedatives and hypnotics	18	—	10	16	4	—	—	12	60
<i>Total sedatives and hypnotics</i>	<i>21,194</i>	<i>20,854</i>	<i>9,186</i>	<i>7,120</i>	<i>4,777</i>	<i>709</i>	<i>1,820</i>	<i>2,589</i>	<i>68,249</i>

(continued)

**Table A3.3 (continued): Drug-related data items<sup>(a)</sup> by jurisdiction, 2006–07**

<b>Drug-related data item</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld<sup>(b)</sup></b>	<b>WA</b>	<b>SA</b>	<b>Tas<sup>(c)</sup></b>	<b>ACT</b>	<b>NT</b>	<b>Australia</b>
Stimulants and hallucinogens									
Amphetamines	4,473	3,399	2,317	4,348	1,375	239	353	84	16,588
Cannabis	7,045	9,993	9,689	2,412	901	963	522	339	31,864
Ecstasy	154	349	570	94	83	37	25	9	1,321
Cocaine	257	84	53	33	18	—	12	—	457
Nicotine	443	282	1,602	128	59	11	8	15	2,548
Balance of stimulants and hallucinogens	14	40	96	119	7	3	7	2	288
<i>Total stimulants and hallucinogens</i>	<i>12,386</i>	<i>14,147</i>	<i>14,327</i>	<i>7,134</i>	<i>2,443</i>	<i>1,253</i>	<i>927</i>	<i>449</i>	<i>53,066</i>
Balance of drugs of concern <sup>(d)</sup>	419	2,666	700	134	72	12	47	122	4,172
<b>Total</b>	<b>41,277</b>	<b>45,104</b>	<b>26,332</b>	<b>17,014</b>	<b>8,712</b>	<b>2,124</b>	<b>3,662</b>	<b>3,496</b>	<b>147,721</b>

(c) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(d) The total number of closed treatment episodes for Queensland may be under-counted because of the exclusion of a number of non-government agencies.

(e) The total number of closed treatment episodes for Tasmania may be under-counted because two agencies supplied drug diversion data only.

(f) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

**Table A3.4: Other drugs of concern<sup>(a)</sup> by jurisdiction, 2007-08**

Other drugs of concern	NSW	Vic	Qld <sup>(b)</sup>	WA	SA	Tas <sup>(c)</sup>	ACT	NT	Australia
Analgesics									
Heroin	1,405	2,904	462	556	237	14	130	37	5,745
Methadone	760	395	140	207	57	21	38	4	1,622
Balance of analgesics <sup>(d)</sup>	1,022	408	460	592	220	53	1,721	49	4,525
<i>Total analgesics</i>	<i>3,187</i>	<i>3,707</i>	<i>1,062</i>	<i>1,355</i>	<i>514</i>	<i>88</i>	<i>1,889</i>	<i>90</i>	<i>11,892</i>
Sedatives and hypnotics									
Alcohol	4,250	9,437	5,067	2,759	912	157	469	12	23,063
Benzodiazepines	2,385	4,452	628	1,214	634	62	233	41	9,649
Balance of sedatives and hypnotics <sup>(d)</sup>	92	—	43	118	11	1	4	2	271
<i>Total sedatives and hypnotics</i>	<i>6,727</i>	<i>13,889</i>	<i>5,738</i>	<i>4,091</i>	<i>1,557</i>	<i>220</i>	<i>706</i>	<i>55</i>	<i>32,983</i>
Stimulants and hallucinogens									
Amphetamines	4,287	8,696	2,165	2,325	832	106	524	82	19,017
Cannabis	8,234	12,932	4,227	4,135	1,597	231	877	186	32,419
Ecstasy	1,155	3,310	1,261	946	215	46	158	63	7,154
Cocaine	933	686	236	327	62	7	51	13	2,315
Nicotine	7,563	7,166	5,116	2,420	1,430	64	932	285	24,976
Balance of stimulants and hallucinogens <sup>(d)</sup>	246	169	507	452	26	14	44	14	1,472
<i>Total stimulants and hallucinogens</i>	<i>22,418</i>	<i>32,959</i>	<i>13,512</i>	<i>10,605</i>	<i>4,162</i>	<i>468</i>	<i>2,586</i>	<i>643</i>	<i>87,353</i>
Balance of drugs of concern <sup>(d)</sup>	424	4,384	218	398	87	4	203	68	5,786
<b>Total</b>	<b>32,756</b>	<b>54,939</b>	<b>20,530</b>	<b>16,449</b>	<b>6,320</b>	<b>780</b>	<b>5,384</b>	<b>856</b>	<b>138,014</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) The total number of closed treatment episodes for Queensland may be under-counted because of the exclusion of a number of non-government agencies.

(c) The total number of closed treatment episodes for Tasmania may be under-counted because two agencies supplied drug diversion data only.

(d) Includes balance of other drugs of concern coded according to ASCDC. See Appendix 5.

**Table A3.5: Principal drug of concern<sup>(a)</sup> by geographical location<sup>(b)</sup>, 2007–08 (per cent)**

Principal drug of concern	Major cities	Inner regional	Outer regional	Remote	Very remote	Australia
Alcohol	42.1	47.8	48.5	71.9	86.7	44.5
Amphetamines	12.7	8.8	6.4	3.5	0.6	11.2
Benzodiazepines	2.0	1.3	0.7	0.3	0.1	1.7
Cannabis	19.3	28.7	27.2	12.5	6.5	21.6
Cocaine	0.4	0.1	0.1	—	—	0.3
Ecstasy	1.0	0.7	0.8	0.3	0.3	0.9
Nicotine	1.4	1.7	4.0	3.7	4.3	1.7
Opioids						
Heroin	13.7	4.0	1.5	0.6	—	10.5
Methadone	1.8	1.1	0.8	0.1	—	1.6
Morphine	0.7	1.1	3.0	1.0	0.1	0.9
<i>Total opioids</i>	17.7	7.8	6.1	1.8	0.6	14.5
All other drugs	3.4	3.0	6.3	5.9	1.0	3.6
<b>Total</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) Geographical location of the treatment agency.

**Table A3.6: Principal drug of concern<sup>(a)</sup> by age group, 2007–08 (per cent)**

Principal drug of concern	Age group (years)						Not stated	Total	Total (number)
	10–19	20–29	30–39	40–49	50–59	60+			
Alcohol	34.2	31.9	42.0	60.0	73.7	83.5	54.3	44.5	65,702
Amphetamines	8.1	15.6	13.7	6.7	2.0	0.4	8.3	11.2	16,588
Benzodiazepines	0.4	1.3	2.1	2.1	2.4	2.2	0.5	1.7	2,487
Cannabis	43.2	27.6	17.8	12.1	6.5	2.1	21.0	21.6	31,864
Cocaine	0.2	0.4	0.4	0.2	0.1	—	0.5	0.3	457
Ecstasy	2.1	1.7	0.3	0.1	<0.1	—	—	0.9	1,321
Nicotine	2.4	1.3	1.1	1.8	3.3	6.9	—	1.7	2,548
Opioids									
Heroin	3.1	13.3	13.8	8.8	4.7	0.6	7.3	10.5	15,571
Methadone	0.2	1.5	2.1	1.8	1.6	0.1	—	1.6	2,296
Morphine	0.2	0.9	1.2	1.1	1.1	0.5	0.8	0.9	1,390
<i>Total opioids</i>	<i>3.7</i>	<i>16.8</i>	<i>18.9</i>	<i>13.9</i>	<i>8.8</i>	<i>2.2</i>	<i>8.8</i>	<i>14.5</i>	<i>21,380</i>
All other drugs <sup>(b)</sup>	5.7	3.4	3.6	3.1	3.1	2.6	6.8	3.6	5,374
<b>Total (per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>..</b>
<b>Total (number)</b>	<b>16,496</b>	<b>47,152</b>	<b>43,034</b>	<b>26,444</b>	<b>10,434</b>	<b>3,761</b>	<b>400</b>	<b>..</b>	<b>147,721</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) Includes balance of other drugs of concern coded according to ASCDC. See Appendix 5.

**Table A3.7: Principal drug of concern<sup>(a)</sup> and all drugs of concern, 2007–08**

<b>Drug of concern</b>	<b>Principal drug of concern reported</b>	<b>Per cent of all closed treatment episodes</b>	<b>All drugs of concern reported, including principal<sup>(b)</sup></b>	<b>Per cent of all closed treatment episodes<sup>(b)</sup></b>
Alcohol	65,702	44.5	88,765	60.1
Amphetamines	16,588	11.2	35,605	24.1
Benzodiazepines	2,487	1.7	12,136	8.2
Cannabis	31,864	21.6	64,283	43.5
Cocaine	457	0.3	2,772	1.9
Ecstasy	1,321	0.9	8,475	5.7
Heroin	15,571	10.5	21,316	14.4
Methadone	2,296	1.6	3,918	2.7
Morphine	1,390	0.9	2,127	1.4
Nicotine	2,548	1.7	27,524	18.6
Other drugs <sup>(c)</sup>	7,497	5.1	18,814	12.7
<b>Total</b>	<b>147,721</b>	<b>—</b>	<b>285,735</b>	<b>—</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) The total for 'all drugs of concern' adds to more than the total number of closed treatment episodes, and the total for 'per cent of all closed treatment episodes' adds to more than 100%, since closed treatment episodes may have more than one drug of concern.

(c) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

Table A3.8: Selected data items by principal drug of concern<sup>(a)</sup>, 2007–08 (per cent)

Client data item	Alcohol	Ampheta- mines	Benzodiaz- epines	Cannabis	Cocaine	Ecstasy	Heroin	Methadone	Other opioids	Other drugs <sup>(b)</sup>	Total
<b>Median age (years)</b>											
Males	36	29	35	25	30	22	32	36	36	31	32
Females	37	28	36	26	28	21	29	32	34	31	32
All persons	36	29	35	26	30	21	31	34	35	31	32
<b>Age group (years)</b>											
10–19	8.6	8.0	2.3	22.4	7.2	26.8	3.3	1.4	2.1	16.9	11.2
20–29	22.9	44.3	25.2	40.8	41.8	60.3	40.2	30.6	26.8	28.1	31.9
30–39	27.5	35.5	36.9	24.1	38.1	10.0	38.0	39.8	37.4	25.3	29.1
40–49	24.2	10.7	22.2	10.1	9.8	2.6	15.0	20.9	24.2	16.3	17.9
50–59	11.7	1.2	10.0	2.1	2.6	0.2	3.1	7.1	7.7	8.5	7.1
60+	4.8	0.1	3.4	0.2	—	—	0.2	0.2	1.6	4.5	2.5
Not stated	0.3	0.2	0.1	0.3	0.4	—	0.2	—	0.2	0.3	0.3
<b>Sex</b>											
Male	69.2	67.6	48.4	70.3	70.7	76.2	66.1	54.7	60.5	59.6	67.7
Female	30.7	32.4	51.5	29.6	29.3	23.7	33.9	45.3	39.3	40.2	32.2
Not stated	0.1	0.1	<0.1	0.1	—	0.1	0.1	—	0.1	0.2	0.1
<b>Indigenous status</b>											
Indigenous	12.9	8.9	5.3	10.9	5.9	4.4	7.0	7.8	8.8	10.4	10.9
Not Indigenous	82.4	86.9	90.1	84.2	89.9	92.0	87.7	87.5	84.5	82.8	84.2
Not stated	4.7	4.2	4.6	4.9	4.2	3.6	5.3	4.6	6.7	6.9	4.9

Table A3.8 (continued): Selected data items by principal drug of concern<sup>(a)</sup>, 2007–08 (per cent)

Client data item	Alcohol	Ampheta- mines	Benzodiaz- epines	Cannabis	Cocaine	Ecstasy	Heroin	Methadone	Other opioids	Other drugs <sup>(b)</sup>	Total
<b>Source of referral</b>											
Self	38.2	35.3	40.9	26.3	41.8	17.2	43.3	34.8	48.4	34.8	35.7
Family member/ friend	3.4	6.4	3.0	3.7	6.6	3.6	4.2	3.6	2.7	3.3	3.9
Medical practitioner	7.9	3.6	13.3	3.6	5.3	2.3	4.0	14.3	14.4	8.2	6.4
Hospital	5.7	2.4	6.3	1.8	2.6	1.1	2.0	10.4	7.3	6.1	4.2
Mental health care service	3.1	2.8	3.7	3.1	0.9	1.5	0.8	1.2	2.1	2.1	2.7
AODTS	9.6	8.4	12.1	7.9	5.0	3.1	12.7	12.9	10.7	6.7	9.3
Other community/health care service	3.5	2.9	2.8	3.3	4.4	1.0	3.0	1.4	2.7	3.9	3.3
Correctional service	10.8	13.1	4.6	9.2	10.3	7.0	11.7	3.0	2.4	5.7	10.1
Police diversion	1.6	3.4	0.6	18.6	2.0	18.7	0.8	0.2	0.7	9.9	5.9
Court diversion	5.1	13.2	5.3	13.7	12.0	37.0	6.8	7.5	3.2	8.1	8.5
Other	10.5	8.0	7.2	8.3	9.0	7.0	10.3	10.1	5.1	10.5	9.5
Not stated	0.5	0.4	0.3	0.5	0.2	0.4	0.3	0.5	0.4	0.7	0.5
<b>Total (per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
<b>Total (number)</b>	<b>65,702</b>	<b>16,588</b>	<b>2,487</b>	<b>31,864</b>	<b>457</b>	<b>1,321</b>	<b>15,571</b>	<b>2,296</b>	<b>3,513</b>	<b>7,922</b>	<b>147,721</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.



**Table A3.9: Selected drug-related data items by principal drug of concern<sup>(a)</sup>, 2007–08 (per cent)**

Drug-related data item	Alcohol	Ampheta- mines	Benzodiaz- epines	Cannabis	Cocaine	Ecstasy	Heroin	Methadone	Other opioids	Other drugs <sup>(b)</sup>	Total
<b>Method of use</b>											
Ingests	98.8	10.7	93.6	1.8	3.9	91.3	1.2	86.1	51.8	24.0	51.9
Smokes	0.4	16.8	0.4	91.4	14.9	1.6	5.5	0.3	0.9	33.1	24.2
Injects	0.2	65.7	4.3	0.4	28.7	2.6	91.3	11.8	43.8	16.6	19.5
Sniffs (powder)	<0.1	3.3	0.1	<0.1	46.0	0.9	0.1	—	0.1	0.4	0.6
Inhales (vapour)	0.1	1.0	0.1	4.1	2.4	0.2	0.5	0.1	0.1	9.2	1.6
Other	0.1	0.2	0.1	0.2	0.4	0.7	0.2	0.1	0.9	4.3	0.4
Not stated	0.3	2.2	1.4	2.1	3.7	2.8	1.2	1.4	2.4	12.4	1.8
<b>Injecting drug use</b>											
Current injector	5.5	51.5	21.4	8.5	29.1	4.8	62.4	33.3	47.5	17.5	19.7
Injected 3–12 months ago	3.9	12.3	10.1	6.1	5.9	2.4	17.0	15.9	7.2	6.0	7.2
Injected 12+ months ago	10.3	8.5	17.2	11.7	9.0	4.8	11.3	28.3	12.6	9.2	10.8
Never injected	66.7	20.7	37.6	61.1	46.0	79.3	4.5	5.2	23.3	45.2	50.2
Not stated	13.7	7.0	13.6	12.6	10.1	8.7	4.8	17.3	9.4	22.1	12.1
<b>Total (per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
<b>Total (number)</b>	<b>65,702</b>	<b>16,588</b>	<b>2,487</b>	<b>31,864</b>	<b>457</b>	<b>1,321</b>	<b>15,571</b>	<b>2,296</b>	<b>3,513</b>	<b>7,922</b>	<b>147,721</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

**Table A3.10: Principal drug of concern<sup>(a)</sup>, with or without other drugs of concern, 2007–08**

<b>Principal drug of concern</b>	<b>With other drugs</b>	<b>With no other drugs</b>	<b>Total closed treatment episodes</b>	<b>Proportion of episodes with 'other drugs' of concern (%)</b>
Alcohol	29,394	36,308	65,702	44.7
Amphetamines	10,935	5,653	16,588	65.9
Benzodiazepines	1,639	848	2,487	65.9
Cannabis	19,081	12,783	31,864	59.9
Cocaine	316	141	457	69.1
Ecstasy	835	486	1,321	63.2
Heroin	10,366	5,205	15,571	66.6
Methadone	1,349	947	2,296	58.8
Other opioids	1,901	1,612	3,513	54.1
All other drugs <sup>(b)</sup>	3,778	4,144	7,922	47.7
<b>Total</b>	<b>79,594</b>	<b>68,127</b>	<b>147,721</b>	<b>53.9</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

**Table A3.11: Other drugs of concern<sup>(a)</sup> nominated for selected principal drugs of concern, 2007-08**

Other drugs of concern	Alcohol		Ampheta- mines		Benzodiaz- epines		Cannabis		Cocaine		Ecstasy		Heroin		Methadone		All principal drugs <sup>(b)</sup>	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Alcohol	24	0.1	4,729	22.5	611	20.9	11,682	35.9	117	19.4	512	32.9	2,852	13.8	260	10.2	23,063	16.7
Amphetamines	6,372	14.0	223	1.1	347	11.9	6,136	18.8	108	17.9	304	19.5	3,978	19.3	281	11.1	19,017	13.8
Benzodiazepines	2,875	6.3	1,210	5.8	21	0.7	1,321	4.1	36	6.0	17	1.1	2,546	12.3	470	18.5	9,649	7.0
Cannabis	16,184	35.5	6,927	32.9	553	18.9	—	—	108	17.9	367	23.6	5,182	25.1	470	18.5	32,419	23.5
Cocaine	583	1.3	639	3.0	41	1.4	385	1.2	—	—	63	4.0	520	2.5	23	0.9	2,315	1.7
Ecstasy	2,012	4.4	1,849	8.8	46	1.6	2,500	7.7	84	14.0	—	—	406	2.0	18	0.7	7,154	5.2
Heroin	1,676	3.7	1,452	6.9	306	10.5	1,244	3.8	59	9.8	17	1.1	—	—	342	13.5	5,745	4.2
Methadone	288	0.6	162	0.8	146	5.0	221	0.7	11	1.8	1	0.1	646	3.1	—	—	1,622	1.2
Nicotine	11,427	25.1	2,199	10.5	338	11.6	6,725	20.7	41	6.8	165	10.6	2,361	11.4	447	17.6	24,976	18.1
Other opioids	1540	3.4	353	1.7	202	6.9	462	1.4	15	2.5	14	0.9	941	4.6	114	4.5	3,874	2.8
Other drugs <sup>(c)</sup>	2,626	5.8	1,285	6.1	315	10.8	1,890	5.8	23	3.8	98	6.3	1,221	5.9	114	4.5	8,180	5.9
<b>Total</b>	<b>45,607</b>	<b>100.0</b>	<b>21,028</b>	<b>100.0</b>	<b>2,926</b>	<b>100.0</b>	<b>32,566</b>	<b>100.0</b>	<b>602</b>	<b>100.0</b>	<b>1,558</b>	<b>100.0</b>	<b>20,653</b>	<b>100.0</b>	<b>2,539</b>	<b>100.0</b>	<b>138,014</b>	<b>100.0</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

(c) Includes balance of other drugs of concern coded according to ASCDC.

**Table A3.12: Selected treatment data items<sup>(a)</sup> by principal drug of concern, 2007–08 (per cent)**

Treatment data item	Alcohol	Ampheta- mines	Benzodiaz- epines	Cannabis	Cocaine	Ecstasy	Heroin	Methadone	Other opioids	Other drugs <sup>(b)</sup>	Total
<b>Main treatment type</b>											
Withdrawal management (detoxification)	18.8	11.0	31.7	12.0	12.7	2.9	22.5	16.2	27.7	15.8	16.9
Counselling	39.2	41.9	30.4	32.8	44.2	37.1	29.3	21.7	18.8	30.2	35.7
Rehabilitation	7.9	13.7	5.6	5.2	9.4	4.9	7.7	5.9	3.9	3.1	7.5
Support and case management only	5.6	8.4	7.0	10.6	7.7	8.6	9.7	10.7	6.0	10.2	7.8
Information and education only	5.0	4.3	1.6	26.2	5.7	34.6	1.2	1.7	2.8	18.5	9.9
Assessment only	16.5	16.9	13.6	10.0	14.7	9.8	16.2	11.5	22.2	10.8	14.7
Other <sup>(c)</sup>	7.1	3.8	10.2	3.2	5.7	2.0	13.4	32.3	18.5	11.4	7.4
<b>Treatment delivery setting</b>											
Non-residential treatment facility	65.0	69.7	63.2	70.0	74.6	79.7	69.4	64.4	62.8	67.1	67.3
Residential treatment facility	22.4	18.2	26.3	12.3	19.9	5.9	22.2	27.9	24.2	10.1	19.1
Home	2.3	1.6	3.5	2.0	—	0.4	1.1	0.6	1.6	2.3	2.0
Outreach setting	8.8	6.6	6.3	13.3	3.9	12.9	6.0	5.8	9.0	18.9	9.7
Other	1.6	3.9	0.8	2.4	1.5	1.1	1.3	1.4	2.4	1.6	2.0
<b>Reason for cessation</b>											
Treatment completed	61.1	50.2	59.0	46.6	57.5	43.4	52.8	53.4	49.4	49.6	54.7
Change in main treatment type	0.5	0.5	0.7	0.4	—	0.4	0.6	0.7	4.7	0.7	0.6
Change in delivery setting	0.6	1.3	1.4	0.4	—	0.5	0.9	1.1	2.3	0.7	0.7
Change in principal drug of concern	<0.1	<0.1	—	<0.1	—	—	<0.1	<0.1	<0.1	<0.1	<0.1

(continued)

**Table A3.12 (continued): Selected treatment data items<sup>(a)</sup> by principal drug of concern, 2007–08 (per cent)**

	Alcohol	Ampheta- mines	Benzodiaz- epines	Cannabis	Cocaine	Ecstasy	Heroin	Methadone	Other opioids	Other drugs <sup>(b)</sup>	Total
Transferred to another service provider	5.4	6.0	8.2	3.5	5.7	2.3	8.6	14.3	11.0	5.3	5.7
Ceased to participate against advice	3.7	4.9	5.1	3.2	3.3	2.0	6.5	4.9	7.2	2.4	4.1
Ceased to participate without notice	16.3	20.7	12.1	14.2	19.3	10.3	17.3	13.5	15.4	16.6	16.3
Ceased to participate involuntary (non-compliance)	1.5	3.3	2.9	2.3	3.9	2.6	2.7	2.4	2.1	0.7	2.0
Ceased to participate at expiation	3.5	5.3	1.8	23.1	5.3	35.4	1.5	0.9	1.1	15.2	8.5
Ceased to participate by mutual agreement	2.4	2.8	4.2	2.4	0.9	1.3	1.7	1.5	1.7	3.2	2.4
Drug court and/or sanctioned by court diversion service	0.1	0.7	0.1	0.2	0.4	0.2	0.4	—	0.1	0.1	0.2
Imprisoned, other than drug court sanctioned	0.5	1.1	0.8	0.5	1.1	0.2	2.4	2.7	1.1	0.7	0.8
Died	0.2	0.1	0.4	<0.1	—	—	0.3	0.3	0.3	0.1	0.2
Other	3.4	2.4	2.8	2.9	2.6	1.5	3.8	3.3	2.8	4.0	3.2
Not stated	0.8	0.5	0.4	0.4	—	0.1	0.4	0.9	0.9	0.7	0.6
<b>Total (per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
<b>Total (number)</b>	<b>65,702</b>	<b>16,588</b>	<b>2,487</b>	<b>31,864</b>	<b>457</b>	<b>1,321</b>	<b>15,571</b>	<b>2,296</b>	<b>3,513</b>	<b>7,922</b>	<b>147,721</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

(c) 'Other' includes 3,178 closed treatment episodes where the main treatment was reported as pharmacotherapy. This represents a small proportion of pharmacotherapy treatment in Australia as agencies whose sole activity is to prescribe and/or dose for methadone or other opioid pharmacotherapies are currently excluded from the AODTS–NMDS (see also Section 5.9).

**Table A3.13: Main treatment type<sup>(a)</sup> by principal drug of concern, clients aged 10–19 years of age, 2007–08 (per cent)**

Treatment data item	Alcohol	Ampheta- mines	Benzodiaz- epines	Cannabis	Cocaine	Ecstasy	Heroin	Methadone	Other opioids	Other drugs <sup>(b)</sup>	Total
<b>Main treatment type</b>											
Withdrawal management (detoxification)	7.1	11.9	27.6	10.5	6.1	3.7	27.8	18.2	26.7	8.2	9.8
Counselling	33.9	38.0	17.2	26.4	48.5	29.9	23.2	33.3	25.3	24.6	29.8
Rehabilitation	4.9	11.1	13.8	4.6	9.1	5.6	5.5	6.1	8.0	4.6	5.3
Support and case management only	18.3	17.5	27.6	18.9	6.1	13.3	22.6	15.2	9.3	25.7	19.1
Information and education only	18.7	6.2	—	29.8	12.1	38.4	1.6	3.0	4.0	24.0	22.6
Assessment only	11.3	12.0	10.3	6.4	18.2	6.8	10.4	15.2	17.3	4.9	8.6
Other <sup>(c)</sup>	5.7	3.2	3.4	3.5	—	2.3	8.9	9.1	9.3	8.0	4.8
<b>Total (per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
<b>Total (number)</b>	<b>5,645</b>	<b>1,329</b>	<b>58</b>	<b>7,125</b>	<b>33</b>	<b>354</b>	<b>508</b>	<b>33</b>	<b>75</b>	<b>1,336</b>	<b>16,496</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

(c) 'Other' includes 18 closed treatment episodes where the main treatment was reported as pharmacotherapy. This represents a small proportion of pharmacotherapy treatment in Australia as agencies whose sole activity is to prescribe and/or dose for methadone or other opioid pharmacotherapies are currently excluded from the AODTS–NMDS (see also Section 5.9).

**Table A3.14: Median duration in days of closed treatment episodes<sup>(a)</sup> by principal drugs of concern, 2007-08**

<b>Principal drug of concern</b>	<b>Median number of days</b>	<b>Total number of treatment episodes</b>
Alcohol	16	65,702
Amphetamines	23	16,588
Benzodiazepines	18	2,487
Cannabis	12	31,864
Cocaine	22	457
Ecstasy	4	1,321
Heroin	29	15,571
Methadone	24	2,296
Other opioids	9	3,513
All other drugs <sup>(b)</sup>	17	7,922
<b>Total</b>	<b>17</b>	<b>147,721</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

Table A3.15: Selected age groups<sup>(a)</sup> by principal drug of concern, 2007-08 (per cent)

Age group (years)	Alcohol	Ampheta- mines	Benzodiaz- epines	Cannabis	Cocaine	Ecstasy	Heroin	Methadone	Other opioids	Other drug <sup>(b)</sup>	Total
10-11	<0.1	<0.1	—	<0.1	—	—	—	—	—	0.2	<0.1
12-13	0.2	<0.1	—	0.4	0.2	—	<0.1	—	<0.1	1.2	0.2
14-15	1.5	0.5	0.3	2.9	0.2	2.1	0.2	—	0.1	4.1	1.6
16-17	2.9	2.6	0.7	7.9	2.2	6.5	0.7	0.6	0.4	5.6	3.8
18-19	4.0	4.8	1.4	11.1	4.6	18.2	2.4	0.8	1.7	5.8	5.5
20+	91.1	91.8	97.6	77.4	92.3	73.2	96.6	98.6	97.7	82.8	88.6
Not stated	0.3	0.2	0.1	0.3	0.4	—	0.2	—	0.2	0.3	0.3
<b>Total (column per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
	(row per cent)										
10-11	21.7	4.3	—	8.7	—	—	—	—	—	65.2	100.0
12-13	36.5	1.1	—	34.0	0.3	—	0.3	—	0.3	27.5	100.0
14-15	40.8	3.9	0.3	39.0	<0.1	1.2	1.0	—	0.1	13.7	100.0
16-17	34.2	7.7	0.3	45.5	0.2	1.5	2.1	0.3	0.3	7.9	100.0
18-19	32.2	9.8	0.4	43.3	0.3	2.9	4.5	0.2	0.7	5.6	100.0
20+	45.7	11.6	1.9	18.8	0.3	0.7	11.5	1.7	2.6	5.0	100.0
Not stated	54.3	8.3	0.5	21.0	0.5	—	7.3	—	1.5	6.8	100.0
<b>Total (row per cent)</b>	<b>44.5</b>	<b>11.2</b>	<b>1.7</b>	<b>21.6</b>	<b>0.3</b>	<b>0.9</b>	<b>10.5</b>	<b>1.6</b>	<b>2.4</b>	<b>5.4</b>	<b>100.0</b>
<b>Total (number)</b>	<b>65,702</b>	<b>16,588</b>	<b>2,487</b>	<b>31,864</b>	<b>457</b>	<b>1,321</b>	<b>15,571</b>	<b>2,296</b>	<b>3,513</b>	<b>7,922</b>	<b>147,721</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.



**Table A3.16: Treatment<sup>(a)</sup> where amphetamines were the principal drug of concern by usual method of use, 2001–02 to 2007–08**

Usual method of use	2001–02	2002–03	2003–04	2004–05	2005–06	2006–07	2007–08
	(number)						
Ingests	913	1,271	1,558	1,671	1,788	1,907	1,778
Smokes	117	173	420	718	1,437	2,377	2,784
Injects	10,487	10,915	11,241	11,309	11,670	11,926	10,900
Sniffs	419	511	630	665	645	622	554
Inhales	4	27	65	59	97	133	168
Other	23	20	26	23	24	31	33
Not stated	248	296	268	335	274	296	371
<b>Total</b>	<b>12,211</b>	<b>13,213</b>	<b>14,208</b>	<b>14,780</b>	<b>15,935</b>	<b>17,292</b>	<b>16,588</b>
	(per cent)						
Ingests	7.5	9.6	11	11.3	11.2	11.0	10.3
Smokes	1.0	1.3	3.0	4.9	9.0	13.7	16.1
Injects	85.9	82.6	79.1	76.5	73.2	69.0	63.0
Sniffs	3.4	3.9	4.4	4.5	4.0	3.6	3.2
Inhales	—	0.2	0.5	0.4	0.6	0.8	1.0
Other	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Not stated	2.0	2.2	1.9	2.3	1.7	1.7	2.1
<b>Total</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

## Treatment program tables

Table A3.17: Selected treatment data items by jurisdiction, 2007-08

Treatment item	NSW	Vic	Qld <sup>(a)</sup>	WA	SA	Tas <sup>(b)</sup>	ACT	NT <sup>(c)</sup>	Australia
<b>Main treatment type</b>									
Withdrawal management (detoxification)	8,292	10,194	1,460	1,978	1,707	33	790	545	24,999
Counselling	12,248	22,269	7,294	10,210	2,383	1,234	1,064	768	57,470
Rehabilitation	3,712	1,868	584	2,721	1,459	98	230	427	11,099
Support and case management only	3,538	6,365	1,018	559	84	87	384	244	12,279
Information and education only	501	402	12,477	503	184	587	308	124	15,086
Assessment only	6,828	4,992	3,362	1,919	2,691	261	701	1,222	21,976
Other <sup>(c)</sup>	6,959	1,448	700	815	522	2	261	382	11,089
<b>Cessation reason</b>									
Treatment completed	27,052	34,535	5,405	7,748	5,408	753	2,323	1,868	85,092
Change in main treatment type	—	—	369	18	81	112	16	311	907
Change in delivery setting	—	—	624	248	116	28	30	19	1,065
Change in principal drug of concern	—	—	3	1	—	1	5	3	13
Transferred to another service provider	3,413	1,624	2,040	922	396	94	76	63	8,628
Ceased to participate against advice	2,700	1,155	872	429	511	77	217	153	6,114
Ceased to participate without notice	5,889	4,639	4,986	5,620	1,673	702	776	587	24,872
Ceased to participate involuntary (non-compliance)	1,167	495	124	399	227	375	119	93	2,999
Ceased to participate at expiation	—	638	9,837	2,058	73	13	12	11	12,642
Ceased to participate by mutual agreement	—	1,572	1,011	802	278	111	49	117	3,940
Drug court and/or sanctioned by court diversion service	115	31	18	141	31	9	8	8	361
Imprisoned, other than drug court sanctioned	379	379	100	183	112	12	43	12	1,220
Died	68	71	37	28	22	3	7	1	237
Other	1,191	2,183	1,189	50	98	12	55	194	4,972
Not stated	104	216	280	58	4	—	2	272	936

(continued)

**Table A3.17 (continued): Selected treatment data items by jurisdiction, 2007–08**

Treatment item	NSW	Vic	Qld <sup>(a)</sup>	WA	SA	Tas <sup>(b)</sup>	ACT <sup>(c)</sup>	NT	Australia
<b>Treatment delivery setting</b>									
Non-residential treatment facility	25,979	33,229	18,122	14,847	7,026	1,970	2,088	1,356	104,617
Residential treatment facility	14,377	7,183	637	1,796	1,527	110	1,513	1,131	28,274
Home	357	1,681	270	583	101	3	1	23	3,019
Outreach setting	626	5,445	7,071	526	281	219	133	841	15,142
Other <sup>(d)</sup>	739	—	795	953	95	—	3	361	2,946
<b>Total</b>	<b>42,078</b>	<b>47,538</b>	<b>26,895</b>	<b>18,705</b>	<b>9,030</b>	<b>2,302</b>	<b>3,738</b>	<b>3,712</b>	<b>153,998</b>

- (a) The total number of closed treatment episodes for Queensland may be under-counted because of the exclusion of a number of non-government agencies.
- (b) The total number of closed treatment episodes for Tasmania may be under-counted because two agencies supplied drug diversion data only.
- (c) The total number of closed treatment episodes in the Australian Capital Territory decreased in 2006–07 because of a review of the reporting practices of one agency.
- (d) 'Other' includes 3,178 closed treatment episodes where the main treatment was reported as pharmacotherapy. This represents a small proportion of pharmacotherapy treatment in Australia as agencies whose sole activity is to prescribe and/or dose for methadone or other opioid pharmacotherapies are currently excluded from the AODTS–NMDS (see also Section 5.9).

**Table A3.18: Other treatment type by jurisdiction, 2007–08<sup>(a)</sup>**

Other treatment type	NSW	Qld <sup>(b)</sup>	WA	SA	Tas <sup>(c)</sup>	ACT	NT	Australia
Withdrawal management (detoxification)	1,089	81	296	235	8	7	32	1,748
Counselling	7,667	301	670	558	29	158	632	10,015
Rehabilitation	632	84	65	160	6	2	110	1,059
Other <sup>(d)</sup>	3,584	2,105	395	1,468	8	400	76	8,036
<b>All other treatments</b>	<b>12,972</b>	<b>2,571</b>	<b>1,426</b>	<b>2,421</b>	<b>51</b>	<b>567</b>	<b>850</b>	<b>20,858</b>

- (a) Excludes analyses of Victorian data as this jurisdiction does not provide data for 'other treatment type'.
- (b) The total number of closed treatment episodes for Queensland may be under-counted because of the exclusion of a number of non-government agencies.
- (c) The total number of closed treatment episodes for Tasmania may be under-counted because two agencies supplied drug diversion data only.
- (d) 'Other' includes 1,671 closed treatment episodes where other/additional treatment type was reported as pharmacotherapy.

**Table A3.19: Selected client data items by main treatment type, 2007-08**

<b>Client item</b>	<b>Withdrawal management (detox)</b>	<b>Counselling</b>	<b>Rehabilitation</b>	<b>Support and case management only</b>	<b>Information and education only</b>	<b>Assessment only</b>	<b>Other<sup>(a)</sup></b>	<b>Total</b>
<b>Median age (years)</b>								
Males	36	32	32	24	25	32	36	32
Females	35	34	32	23	26	32	34	33
<i>All persons</i>	35	33	32	24	25	32	35	32
<b>Age group (years)</b>								
10-19	6.5	9.3	7.9	30.1	25.2	6.6	7.4	11.4
20-29	25.4	30.4	33.5	34.0	38.0	35.0	25.5	31.1
30-39	31.5	29.5	33.5	19.4	19.7	31.5	28.5	28.6
40-49	22.9	18.6	17.6	10.5	11.8	17.9	20.8	18.0
50-59	10.3	8.5	5.8	3.7	3.9	6.6	10.8	7.7
60+	3.3	3.2	1.6	1.2	1.2	2.4	6.9	2.9
Not stated	0.2	0.4	0.2	1.0	0.2	<0.1	<0.1	0.3
<b>Client type</b>								
Own drug use	100.0	91.7	100.0	93.8	97.1	99.1	99.1	95.9
Others' drug use	—	8.3	—	6.2	2.9	0.9	0.9	4.1
<b>Sex</b>								
Male	65.0	64.0	66.3	62.9	72.0	73.9	62.3	66.3
Female	35.0	35.8	33.6	37.0	28.0	26.0	37.6	33.6
Not stated	0.1	0.1	0.1	0.1	<0.1	0.1	0.1	0.1

(continued)

**Table A3.19 (continued): Selected client data items by main treatment type, 2007–08**

<b>Client item</b>	<b>Withdrawal management (detox)</b>	<b>Counselling</b>	<b>Rehabilitation</b>	<b>Support and case management only</b>	<b>Information and education only</b>	<b>Assessment only</b>	<b>Other<sup>(a)</sup></b>	<b>Total</b>
<b>Indigenous status</b>								
Indigenous	8.1	10.0	13.1	11.1	12.2	13.2	9.8	10.7
Not Indigenous	87.1	84.6	85.0	84.1	83.4	80.6	86.1	84.4
Not stated	4.7	5.4	1.9	4.8	4.4	6.2	4.1	4.9
<b>Source of referral</b>								
Self	53.5	39.9	33.1	33.7	13.7	28.8	26.0	36.0
Family member/ friend	3.8	5.2	7.5	4.7	1.9	4.4	1.3	4.4
Medical practitioner	8.2	4.5	3.2	2.9	0.7	3.3	31.5	6.3
Hospital	4.7	2.3	4.0	2.1	2.4	5.7	13.4	4.1
Mental health care service <sup>(b)</sup>	2.1	3.1	2.4	2.1	1.0	1.8	6.2	2.7
AODTS	14.4	8.2	20.1	9.5	1.4	5.8	9.6	9.3
Other community/health care service <sup>(c)</sup>	4.1	4.0	5.7	4.6	0.9	2.0	1.6	3.4
Correctional service	1.0	8.2	9.8	7.9	3.1	32.0	3.5	9.7
Police diversion	0.2	2.2	1.0	1.4	45.6	1.5	0.2	5.7
Court diversion	1.9	7.3	7.3	15.8	26.6	4.9	1.5	8.2
Other	5.8	14.1	5.8	15.0	2.5	9.3	4.9	9.7
Not stated	0.3	1.1	0.3	0.5	0.1	0.5	0.2	0.6
<b>Total (per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
<b>Total (number)</b>	<b>24,999</b>	<b>57,470</b>	<b>11,099</b>	<b>12,279</b>	<b>15,086</b>	<b>21,976</b>	<b>11,089</b>	<b>153,998</b>

(a) 'Other' includes 3,178 closed treatment episodes where the main treatment was reported as pharmacotherapy. This represents a small proportion of pharmacotherapy treatment in Australia as agencies whose sole activity is to prescribe and/or dose for methadone or other opioid pharmacotherapies are currently excluded from the AODTS–NMDS (see also Section 5.9).

(b) Includes residential and non-residential services.

(c) Includes outpatient clinics and aged care facilities.

**Table A3.20: Selected treatment items by main treatment type, 2007–08 (per cent)**

Treatment item	Withdrawal management (detox)	Counselling	Rehabilitation	Support and case management only	Information and education only	Assessment only	Other <sup>(e)</sup>	Total
<b>Treatment delivery setting</b>								
Non-residential treatment facility	29.5	93.6	28.9	46.4	71.4	83.5	49.1	67.9
Residential treatment facility	60.1	0.4	65.4	0.8	0.2	4.2	42.7	18.4
Home	8.3	1.1	0.2	0.6	0.5	0.3	0.4	2.0
Outreach setting	2.0	3.5	2.2	49.9	24.4	8.7	6.0	9.8
Other	0.1	1.4	3.2	2.2	3.6	3.3	1.7	1.9
<b>Reason for cessation</b>								
Treatment completed	64.5	51.8	37.5	62.0	18.8	82.0	59.2	55.3
Change in main treatment type	0.6	0.4	0.3	0.3	0.4	1.5	0.8	0.6
Change in delivery setting	0.7	0.5	1.6	0.5	0.5	0.8	0.6	0.7
Change in principal drug of concern	—	<0.1	<0.1	<0.1	—	<0.1	<0.1	<0.1
Transferred to another service provider	4.9	5.4	6.3	7.0	1.3	3.3	16.5	5.6
Ceased to participate against advice	10.6	1.7	16.2	2.6	0.5	0.6	1.7	4.0
Ceased to participate without notice	10.5	26.2	15.7	13.6	5.2	7.9	11.7	16.2
Ceased to participate involuntarily (non-compliance)	2.3	1.0	11.1	2.1	1.6	0.1	0.6	1.9
Ceased to participate at expiration	0.5	3.9	1.4	0.7	65.9	0.4	0.3	8.2
Ceased to participate by mutual agreement	2.6	3.6	4.4	2.1	0.8	1.3	0.7	2.6
Drug court and/or sanctioned by court diversion service	<0.1	0.3	0.5	0.4	<0.1	0.2	0.1	0.2

(continued)

**Table A3.20 (continued): Selected treatment items by main treatment type, 2007–08 (per cent)**

Treatment item	Withdrawal management (detox)	Counselling	Rehabilitation	Support and case management only	Information and education only	Assessment only	Other <sup>(a)</sup>	Total
Imprisoned, other than drug court sanctioned	0.1	1.0	0.9	1.8	0.1	0.3	2.3	0.8
Died	0.1	0.2	0.1	0.1	<0.1	0.1	0.5	0.2
Other	1.9	3.5	2.5	6.2	4.6	1.1	4.7	3.2
Not stated	0.5	0.5	1.7	0.6	0.2	0.8	0.4	0.6
<b>Total (per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
<b>Total (number)</b>	<b>24,999</b>	<b>57,470</b>	<b>11,099</b>	<b>12,279</b>	<b>15,086</b>	<b>21,976</b>	<b>11,089</b>	<b>153,998</b>

(a) 'Other' includes 3,178 closed treatment episodes where the main treatment was reported as pharmacotherapy. This represents a small proportion of pharmacotherapy treatment in Australia as agencies whose sole activity is to prescribe and/or dose for methadone or other opioid pharmacotherapies are currently excluded from the AODTS–NMDS (see also Section 5.9).

Table A3.21: Selected age groups by main treatment type, 2007–08 (per cent)

Age group (years)	Withdrawal management (detox)	Counselling	Rehabilitation	Support and case management only (column per cent)	Information and education only	Assessment only	Other <sup>(a)</sup>	Total
10–11	<0.1	0.1	—	0.1	<0.1	0.1	0.1	0.1
12–13	0.1	0.3	0.1	0.9	0.6	0.1	0.1	0.3
14–15	0.8	1.6	0.8	7.3	3.4	0.4	1.1	1.8
16–17	2.0	3.1	2.8	9.5	9.6	1.6	2.6	3.8
18–19	3.6	4.2	4.2	12.4	11.6	4.4	3.5	5.4
20+	93.3	90.3	91.9	68.8	74.6	93.3	92.6	88.2
Not stated	0.2	0.4	0.2	1.0	0.2	<0.1	<0.1	0.3
<b>Total (column per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>
				(row per cent)				
10–11	2.0	67.3	—	6.9	2.0	12.9	8.9	100.0
12–13	6.5	37.2	2.9	23.8	20.1	6.5	2.9	100.0
14–15	7.1	32.2	3.0	31.7	18.2	3.3	4.5	100.0
16–17	8.4	30.6	5.3	19.9	24.6	6.1	4.9	100.0
18–19	10.6	28.6	5.6	18.2	20.9	11.5	4.6	100.0
20+	17.2	38.2	7.5	6.2	8.3	15.1	7.6	100.0
Not stated	9.4	52.2	3.5	26.3	6.4	1.2	1.0	100.0
<b>Total (row per cent)</b>	<b>16.2</b>	<b>37.3</b>	<b>7.2</b>	<b>8.0</b>	<b>9.8</b>	<b>14.3</b>	<b>7.2</b>	<b>100.0</b>
<b>Total (number)</b>	<b>24,999</b>	<b>57,470</b>	<b>11,099</b>	<b>12,279</b>	<b>15,086</b>	<b>21,976</b>	<b>11,089</b>	<b>153,998</b>

(a) 'Other' includes 3,178 closed treatment episodes where the main treatment was reported as pharmacotherapy. This represents a small proportion of pharmacotherapy treatment in Australia as agencies whose sole activity is to prescribe and/or dose for methadone or other opioid pharmacotherapies are currently excluded from the AODTS–NMDS (see also Section 5.9).



**Table A3.22: Median duration in days of closed treatment episodes by main treatment type, 2007–08**

<b>Main treatment type</b>	<b>Median number of days</b>	<b>Total number of treatment episodes</b>
Withdrawal management (detoxification)	8	24,999
Counselling	47	57,470
Rehabilitation	37	11,099
Support and case management only	52	12,279
Information and education only	1	15,086
Assessment only	2	21,976
Other <sup>(a)</sup>	8	11,089
<b>Total</b>	<b>17</b>	<b>153,998</b>

(a) 'Other' includes 3,178 closed treatment episodes where the main treatment was reported as pharmacotherapy. This represents a small proportion of pharmacotherapy treatment in Australia as agencies whose sole activity is to prescribe and/or dose for methadone or other opioid pharmacotherapies are currently excluded from the AODTS–NMDS.

**Table A3.23: Principal drug of concern<sup>(a)</sup> by main treatment type, 2007–08 (per cent)**

Principal drug of concern	Withdrawal management (detox)								Total
	management	Counselling	Rehabilitation	Support and case management only	Information and education only	Assessment only	Other <sup>(b)</sup>		
Alcohol	49.5	48.9	46.8	31.7	22.3	49.6	42.4	44.5	
Amphetamines	7.3	13.2	20.5	12.0	4.9	12.9	5.7	11.2	
Benzodiazepines	3.2	1.4	1.3	1.5	0.3	1.6	2.3	1.7	
Cannabis	15.3	19.8	14.9	29.4	57.1	14.7	9.2	21.6	
Cocaine	0.2	0.4	0.4	0.3	0.2	0.3	0.2	0.3	
Ecstasy	0.2	0.9	0.6	1.0	3.1	0.6	0.2	0.9	
Heroin	14.0	8.7	10.8	13.0	1.3	11.6	19.0	10.5	
Methadone	1.5	0.9	1.2	2.1	0.3	1.2	6.8	1.6	
Other opioids	3.9	1.3	1.2	1.8	0.7	3.6	5.9	2.4	
Other drugs <sup>(c)</sup>	5.0	4.5	2.2	7.0	10.0	3.9	8.2	5.4	
<b>Total (per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	
<b>Total (number)</b>	<b>24,999</b>	<b>52,697</b>	<b>11,099</b>	<b>11,518</b>	<b>14,642</b>	<b>21,778</b>	<b>10,988</b>	<b>147,721</b>	

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) 'Other' includes 3,178 closed treatment episodes where the main treatment was reported as pharmacotherapy. This represents a small proportion of pharmacotherapy treatment in Australia as agencies whose sole activity is to prescribe and/or dose for methadone or other opioid pharmacotherapies are currently excluded from the AODTS–NMDS.

(c) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

**Table A3.24: Principal drug of concern<sup>(a)</sup> by main treatment type, clients aged 10–19 years of age, 2007–08 (per cent)**

Principal drug of concern	Withdrawal management (detox)								Total
	management	only	Counselling	Rehabilitation	Support and case management only	Information and education only	Assessment only	Other <sup>(b)</sup>	
Alcohol	24.9	39.0	31.5	32.8	28.3	44.9	41.2	34.2	
Amphetamines	9.8	10.3	16.9	7.4	2.2	11.2	5.5	8.1	
Benzodiazepines	1.0	0.2	0.9	0.5	—	0.4	0.3	0.4	
Cannabis	46.3	38.3	37.0	42.8	56.8	31.9	31.5	43.2	
Cocaine	0.1	0.3	0.3	0.1	0.1	0.4	—	0.2	
Ecstasy	0.8	2.2	2.3	1.5	3.6	1.7	1.0	2.1	
Heroin	8.7	2.4	3.2	3.6	0.2	3.7	5.7	3.1	
Methadone	0.4	0.2	0.2	0.2	<0.1	0.4	0.4	0.2	
Other opioids	1.2	0.4	0.7	0.2	0.1	0.9	0.9	0.5	
Other drugs <sup>(c)</sup>	6.8	6.7	6.9	10.9	8.6	4.6	13.6	8.1	
<b>Total (per cent)</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>	
<b>Total (number)</b>	<b>1,619</b>	<b>4,908</b>	<b>878</b>	<b>3,151</b>	<b>3,731</b>	<b>1,422</b>	<b>787</b>	<b>16,496</b>	

(a) Excludes treatment episodes for clients seeking treatment for the drug use of others.

(b) 'Other' includes 18 closed treatment episodes where the main treatment was reported as pharmacotherapy. This represents a small proportion of pharmacotherapy treatment in Australia as agencies whose sole activity is to prescribe and/or dose for methadone or other opioid pharmacotherapies are currently excluded from the AODTS–NMDS (see also Section 5.9).

(c) Includes balance of principal drugs of concern coded according to ASCDC. See Appendix 5.

## Appendix 4: Australian Standard Geographical Classification

In 2001, the ABS included the Remoteness Area Structure (ASGC Remoteness Areas) to the Australian Standard Geographical Classification (ASGC). It is based on an enhanced measure of remoteness (ARIA+) developed by the National Key Centre for Social Applications of Geographical Information (AIHW 2004b).

The ASGC Remoteness Areas replace the former national standard classification of Rural, Remote and Metropolitan Area (RRMA). The Remoteness Area classification summarises the remoteness of an area based on the road distance to different-sized urban centres, where the population size of an urban centre is considered to govern the range and type of services available.

There are five major Remoteness Areas into which the statistical local areas of the alcohol and other drug treatment agencies are placed:

- Major cities of Australia
- Inner regional Australia
- Outer regional Australia
- Remote Australia
- Very remote Australia.

For further information on how Remoteness Areas are calculated, see *Rural, regional and remote health: a guide to remoteness classifications* (AIHW 2004b).

# Appendix 5: Australian Standard Classification of Drugs of Concern

The main classification structure is presented below. For detailed information, supplementary codes and the full version of the coding index, see Australian Standard Classification of Drugs of Concern (ABS 2000).

## **1 ANALGESICS**

### **11 Organic Opiate Analgesics**

- 1101 Codeine
- 1102 Morphine
- 1199 Organic Opiate Analgesics, n.e.c.

### **12 Semisynthetic Opioid Analgesics**

- 1201 Buprenorphine
- 1202 Heroin
- 1203 Oxycodone
- 1299 Semisynthetic Opioid Analgesics, n.e.c.

### **13 Synthetic Opioid Analgesics**

- 1301 Fentanyl
- 1302 Fentanyl analogues
- 1303 Levomethadyl acetate hydrochloride
- 1304 Meperidine analogues
- 1305 Methadone
- 1306 Pethidine
- 1399 Synthetic Opioid Analgesics, n.e.c.

### **14 Non Opioid Analgesics**

- 1401 Acetylsalicylic acid
- 1402 Paracetamol
- 1499 Non Opioid Analgesics, n.e.c.

## **2 SEDATIVES AND HYPNOTICS**

### **21 Alcohols**

2101	Ethanol
2102	Methanol
2199	Alcohols, n.e.c.

### **22 Anaesthetics**

2201	Gamma-hydroxybutyrate
2202	Ketamine
2203	Nitrous oxide
2204	Phencyclidine
2299	Anaesthetics, n.e.c.

### **23 Barbiturates**

2301	Amylobarbitone
2302	Methylphenobarbitone
2303	Phenobarbitone
2399	Barbiturates, n.e.c.

### **24 Benzodiazepines**

2401	Alprazolam
2402	Clonazepam
2403	Diazepam
2404	Flunitrazepam
2405	Lorazepam
2406	Nitrazepam
2407	Oxazepam
2408	Temazepam
2499	Benzodiazepines, n.e.c.

### **29 Other Sedatives and Hypnotics**

2901	Chlormethiazole
2902	Kava lactones
2903	Zopiclone
2999	Other Sedatives and Hypnotics, n.e.c.

### **3 STIMULANTS AND HALLUCINOGENS**

#### **31 Amphetamines**

3101	Amphetamine
3102	Dexamphetamine
3103	Methamphetamine
3199	Amphetamines, n.e.c.

#### **32 Cannabinoids**

3201	Cannabinoids
------	--------------

#### **33 Ephedra Alkaloids**

3301	Ephedrine
3302	Norephedrine
3303	Pseudoephedrine
3399	Ephedra Alkaloids, n.e.c.

#### **34 Phenethylamines**

3401	DOB
3402	DOM
3403	MDA
3404	MDEA
3405	MDMA
3406	Mescaline
3407	PMA
3408	TMA
3499	Phenethylamines, n.e.c.

#### **35 Tryptamines**

3501	Atropinic alkaloids
3502	Diethyltryptamine
3503	Dimethyltryptamine
3504	Lysergic acid diethylamide
3505	Psilocybin
3599	Tryptamines, n.e.c.

#### **36 Volatile Nitrates**

3601	Amyl nitrate
3602	Butyl nitrate
3699	Volatile Nitrates, n.e.c.

### **39 Other Stimulants and Hallucinogens**

3901	Caffeine
3902	Cathinone
3903	Cocaine
3904	Methcathinone
3905	Methylphenidate
3906	Nicotine
3999	Other Stimulants and Hallucinogens, n.e.c.

## **4 ANABOLIC AGENTS AND SELECTED HORMONES**

### **41 Anabolic Androgenic Steroids**

4101	Boldenone
4102	Dehydroepiandrosterone
4103	Fluoxymesterone
4104	Mesterolone
4105	Methandriol
4106	Methenolone
4107	Nandrolone
4108	Oxandrolone
4111	Stanozolol
4112	Testosterone
4199	Anabolic Androgenic Steroids, n.e.c.

### **42 Beta<sub>2</sub> Agonists**

4201	Eformoterol
4202	Fenoterol
4203	Salbutamol
4299	Beta <sub>2</sub> Agonists, n.e.c.

### **43 Peptide Hormones, Mimetics and Analogues**

4301	Chorionic gonadotrophin
4302	Corticotrophin
4303	Erythropoietin
4304	Growth hormone
4305	Insulin
4399	Peptide Hormones, Mimetics and Analogues, n.e.c.



#### **49 Other Anabolic Agents and Selected Hormones**

- 4901 Sulfonylurea hypoglycaemic agents
- 4902 Tamoxifen
- 4903 Thyroxine
- 4999 Other Anabolic Agents and Selected Hormones, n.e.c.

### **5 ANTIDEPRESSANTS AND ANTIPSYCHOTICS**

#### **51 Monoamine Oxidase Inhibitors**

- 5101 Moclobemide
- 5102 Phenelzine
- 5103 Tranylcypromine
- 5199 Monoamine Oxidase Inhibitors, n.e.c.

#### **52 Phenothiazines**

- 5201 Chlorpromazine
- 5202 Fluphenazine
- 5203 Pericyazine
- 5204 Thioridazine
- 5205 Trifluoperazin
- 5299 Phenothiazines, n.e.c.

#### **53 Serotonin Reuptake Inhibitors**

- 5301 Citalopram
- 5302 Fluoxetine
- 5303 Paroxetine
- 5304 Sertraline
- 5399 Serotonin Reuptake Inhibitors, n.e.c.

#### **54 Thioxanthenes**

- 5401 Flupenthixol
- 5402 Thiothixene
- 5499 Thioxanthenes, n.e.c.

#### **55 Tricyclic Antidepressants**

- 5501 Amitriptyline
- 5502 Clomipramine
- 5503 Dothiepin
- 5504 Doxepin
- 5505 Nortriptyline
- 5599 Tricyclic Antidepressants, n.e.c.

**59 Other Antidepressants and Antipsychotics**

- 5901 Butyrophenones
- 5902 Lithium
- 5903 Mianserin
- 5999 Other Antidepressants and Antipsychotics, n.e.c.

**6 VOLATILE SOLVENTS**

**61 Aliphatic Hydrocarbons**

- 6101 Butane
- 6102 Petroleum
- 6103 Propane
- 6199 Aliphatic Hydrocarbons, n.e.c.

**62 Aromatic Hydrocarbons**

- 6201 Toluene
- 6202 Xylene
- 6299 Aromatic Hydrocarbons, n.e.c.

**63 Halogenated Hydrocarbons**

- 6301 Bromochlorodifluoromethane
- 6302 Chloroform
- 6303 Tetrachloroethylene
- 6304 Trichloroethane
- 6305 Trichloroethylene
- 6399 Halogenated Hydrocarbons, n.e.c.

**69 Other Volatile Solvents**

- 6901 Acetone
- 6902 Ethyl acetate
- 6999 Other Volatile Solvents, n.e.c.

**9 MISCELLANEOUS DRUGS OF CONCERN**

**91 Diuretics**

- 9101 Antikaliuretics
- 9102 Loop diuretics
- 9103 Thiazides
- 9199 Diuretics, n.e.c.

**92 Opioid Antagonists**

9201 Naloxone

9202 Naltrexone

9299 Opioid Antagonists, n.e.c.

**99 Other Drugs of Concern**

9999 Other Drugs of Concern

## **Appendix 6: Alcohol and other drug treatment provided by services funded to assist Aboriginal and Torres Strait Islander peoples**

The number of treatment episodes reported through the AODTS–NMDS for Aboriginal and Torres Strait Islander peoples do not represent all alcohol and other drug treatments provided to Indigenous people in Australia for 2007–08. The majority of Australian Government-funded Aboriginal and Torres Strait Islander substance use-specific services or Aboriginal and Torres Strait Islander primary health care services report to two other data collections:

- Drug and Alcohol Service Report (DASR), coordinated by the Office for Aboriginal and Torres Strait Islander Health (OATSIH) in the Australian Government Department of Health and Ageing (DoHA). The DASR collects information from all Australian Government-funded Aboriginal and Torres Strait Islander substance use-specific services (agencies). In 2007–08, 46 services (100% of funded services) provided DASR data.
- Service Activity Reporting (SAR), a joint collection by the National Aboriginal Community Controlled Health Organisation (NACCHO) and OATSIH. The SAR collects information from Aboriginal and Torres Strait Islander primary health care services that receive Australian Government funding. In 2006–07, 146 of 147 services (99% of funded services) provided SAR data.

This appendix presents a selection of data from these collections. The SAR, DASR and AODTS–NMDS have different collection purposes, scope and counting rules. For example, the SAR and DASR collect service-level estimates for client numbers and episodes of care whereas the AODTS–NMDS collects unit records for closed treatment episodes. The definitions of ‘closed treatment episodes’ (AODTS–NMDS) and ‘episodes of care’ (SAR/DASR) are not consistent.

In 2007–08, 8 out of the 46 Australian Government-funded services reporting in the DASR also reported under the AODTS–NMDS, and 11 out of the 147 Aboriginal and Torres Strait Islander primary health care services reporting in the SAR also reported under the AODTS–NMDS.

### **Box A6.1: Comparison of treatment episode definitions in the SAR, DASR and AODTS-NMDS**

The **DASR** definition of 'episode of care' starts at admission and ends at discharge (from residential treatment/rehabilitation and sobering-up/respice). In the case of 'other care', the definition of 'episode of care' relates more to the number of visits or phone calls undertaken with clients. In contrast to the definition of 'closed treatment episode' used in the AODTS-NMDS, the definition used in this collection does not require agencies to begin a new 'episode of care' when the main treatment type ('treatment type') or primary drug of concern ('substance/drug') changes. It is therefore likely that this concept of 'episode of care' produces smaller estimates of activity than the AODTS-NMDS concept of 'closed treatment episode'.

The **SAR** definition of 'episode of care' relates to each time a person sees someone from the health clinic for health care. If a person sees more than one staff member on the same day this is considered one episode and there can only ever be one episode of care on a single day. However, if a person sees staff members (the same or different staff members) on 2 days, this is considered two episodes. In contrast to the AODTS-NMDS definition of 'closed treatment episode', this definition of 'episode of care' does not relate to a period of specific treatment (for example, for a particular drug of concern). It is therefore likely that this concept of 'episode of care' produces larger estimates of activity than the AODTS-NMDS concept of 'closed treatment episode'.

The **DASR** and **SAR** collections record information about clients of any age, whereas the AODTS-NMDS reports only about clients aged 10 years and over. Any comparisons drawn between the collections should therefore be made with caution.

## **The Drug and Alcohol Service Report (DASR): substance use-specific services**

In 2007–08, approximately 22,800 people were seen by Australian Government-funded Aboriginal and Torres Strait Islander substance use-specific services.

**Table A6.1: Estimated number of clients seen by Australian Government-funded Aboriginal and Torres Strait Islander substance use-specific services (DASR) by jurisdiction and Indigenous status, 2007–08**

<b>Indigenous status</b>	<b>NSW &amp; Vic</b>	<b>Qld</b>	<b>WA</b>	<b>SA</b>	<b>NT</b>	<b>Australia</b>
Indigenous	1,200	3,500	4,300	4,500	4,000	17,500
Non-Indigenous	300	2,400	500	2,000	100	5,300
<b>Total (number)</b>	<b>1,500</b>	<b>5,900</b>	<b>4,800</b>	<b>6,500</b>	<b>4,100</b>	<b>22,800</b>
<b>Total (per cent)</b>	<b>7</b>	<b>26</b>	<b>21</b>	<b>29</b>	<b>18</b>	<b>100</b>

*Note:* Figures are rounded to the nearest hundred.

*Source:* Australian Government Department of Health and Ageing analysis of the 2007–08 Drug and Alcohol Service Report.

In addition to the number of clients seen, treatment agencies report on the drugs for which they provide treatment during the year. During 2007–08, all (100%) Australian Government-funded Aboriginal and Torres Strait Islander substance use-specific services (agencies) reported providing treatment or assistance for client alcohol use (Table A6.2). Other common substances/drugs for which services provided treatment or assistance included cannabis (96%), multiple drug use (78%), and amphetamines and tobacco/nicotine (72% and 76% respectively).

**Table A6.2: Substances/drugs for which treatment/assistance was provided by Australian Government-funded Aboriginal and Torres Strait Islander substance use specific services, 2007–08**

Substance/drug	Percentage of services that provided treatment/assistance for this substance/drug
Alcohol	100
Cannabis (marijuana, gunja, yamdi)	96
Multiple drug use (two or more drugs/substances)	78
Amphetamines (speed, uppers)	72
Tobacco/nicotine	76
Petrol	43
Other solvents/inhalants (chroming, paint, glue, aerosol cans)	43
Benzodiazepines (sleeping pills, Valium, Rohypnol)	54
Heroin	48
Cocaine (coke, crack)	28
Barbiturates (downers, Phenobarbital, Amytal)	28
Methadone	33
Ecstasy/MDMA	41
Morphine	30
LSD (acid, trips)	17
Steroids/anabolic agents	9
Kava	4
Other	2

*Source:* Australian Government Department of Health and Ageing analysis of the 2007–08 Drug and Alcohol Service Report.

### **The Service Activity Report: primary care health services**

Aboriginal and Torres Strait Islander primary health care services provide a wide variety of health care services, including extended care roles (for example, diagnosis and treatment of illness and disease, 24-hour emergency care, dental/hearing/optometry services), preventive health care (for example, health screening for children and adults), health-related community support (for example, school-based activities, transport to medical appointments) and support in relation to substance use issues. The number of clients who attended Aboriginal and Torres Strait Islander primary health care services and received alcohol or other drug treatment is not collected in the SAR. Similarly, the number of reported episodes of care that related solely or partially to alcohol or other drug treatment is not collected.

However, the drug types for which treatment was provided are known. In 2006–07, most services covered issues relating to alcohol (90), tobacco/nicotine (88%) or cannabis (85%) (Table A6.5). Many service outlets also provided treatment for multiple drug use (63%), benzodiazepines (52%) and other solvents/inhalants (50%).

**Table A6.3: Substances/drugs for which Australian Government-funded Aboriginal and Torres Strait Islander primary health care services cover substance use issues on an individual basis as they arise, 2006–07**

<b>Substance/drug</b>	<b>Percentage of services that cover substance use issues on an individual basis as they arise</b>
Alcohol	90
Tobacco/nicotine	88
Cannabis (marijuana, gunja, yamdi)	85
Multiple drug use (two or more drugs/substances)	63
Benzodiazepines (sleeping pills, Valium, Rohypnol)	52
Other solvents/inhalants (chroming, paint, glue, aerosol cans)	50
Petrol	46
Heroin	43
Methadone	48
Amphetamines (speed, uppers)	50
Barbiturates (downers, Phenobarbital, Amytal)	39
Morphine	29
Cocaine (coke, crack)	26
Ecstasy/MDMA	37
LSD (acid, trips)	19
Steroids/anabolic agents	16
Kava	14
Other	6

*Source:* Australian Government Department of Health and Ageing analysis of the 2006–07 Service Activity Report.

## Appendix 7: Mapping of ICD-10-AM codes to ASCDC output categories

The following table provides technical details about the mapping process applied to produce the hospital separations data in Chapter 4. Please note that these codes are not a complete list of ICD-10-AM codes for which a hospital separation may be attributed as (wholly or partially) drug-related. These mapping details apply to analyses of principal and additional diagnoses presented.

**Table A7.1: Mapping of ICD-10-AM codes to ASCDC output categories**

<b>Drug of concern identified in principal diagnosis</b>	<b>ICD-10-AM codes</b>
<b>Analgesics</b>	
Opioids (includes heroin, opium, morphine & methadone)	F11 (11.0–11.9), T40.0, T40.1, T40.2, T40.3, T40.4
Non opioid analgesics (includes paracetamol)	T39.0, T39.1, T39.9
<b>Sedatives and hypnotics</b>	
Alcohol	F10 (10.0–10.9), T51 (51.0–51.9), Z71.4, Z72.1
Other sedatives & hypnotics (includes barbiturates & benzodiazepines; excludes alcohol)	F13 (13.0–13.9), F55.6, T41.2, T42.6, T42.3, T42.4, T42.7
<b>Stimulants and hallucinogens</b>	
Cannabinoids (includes cannabis)	F12 (12.0–12.9), T40.7
Hallucinogens (includes LSD & ecstasy)	F16 (16.0–16.9), T40.8, T40.9
Cocaine	F14 (14.0–14.9), T40.5
Tobacco & nicotine	F17 (17.0–17.9), T65.2, Z72.0
Other stimulants (includes amphetamines, pseudoephedrine, volatile nitrates & caffeine)	F15 (15.0–15.9), T40.6, T44.9, T43.6, T46.3
<b>Antidepressants and antipsychotics</b>	
Antidepressants & antipsychotics	T43 (43.0–43.5)
<b>Volatile solvents</b>	
Volatile solvents	F18 (18.0–18.9), T52 (52.0–52.9), T53.6, T53.7, T59.8
<b>Other and unspecified drugs of concern</b>	
Multiple drug use	F19 (19.0–19.9)
Unspecified drug use & other drugs not elsewhere classified (includes psychotropic drugs not elsewhere classified; diuretics; anabolic and androgenic steroids & opiate antagonists)	Z71.5, Z72.2, T38.7, T43.8, T43.9, T50.1, T50.2, T50.3, T50.7



# References

- ABS (Australian Bureau of Statistics) 2000. Australian standard classification of drugs of concern. ABS cat. no. 1248.0. Canberra: ABS.
- AIHW 2002. Alcohol and other drug treatment services in Australia 2000–01: first report on the national minimum data set. Cat. no. HSE 22. Canberra: AIHW.
- AIHW 2003. Alcohol and other drug treatment services in Australia 2001–02: report on the national minimum data set. Cat. no. HSE 28. Canberra: AIHW.
- AIHW 2004a. Alcohol and other drug treatment services in Australia 2002–03: report on the national minimum data set. Cat. no. HSE 33. Canberra: AIHW.
- AIHW 2004b. Rural, regional and remote health: a guide to remoteness classifications. Cat. no. PHE 53. Canberra: AIHW.
- AIHW 2005. Alcohol and other drug treatment services in Australia 2003–04: report on the national minimum data set. Cat. no. HSE 100. Canberra: AIHW.
- AIHW 2006. Alcohol and other drug treatment services in Australia 2004–05: report on the national minimum data set. Cat. no. HSE 43. Canberra: AIHW.
- AIHW 2007. Alcohol and other drug treatment services in Australia 2005–06: report on the National Minimum Data Set. Drug Treatment Series no.7. Cat. no. HSE 53. Canberra: AIHW.
- AIHW 2008a. Alcohol and other drug treatment services in Australia 2006–07: report on the National Minimum Data Set. Drug Treatment Series no.8. Cat. no. HSE 59. Canberra: AIHW.
- AIHW 2008b. 2007 National Drug Strategy Household Survey: first results. Drug statistics series no. 20. Cat. no. PHE 98. Canberra: AIHW.
- AIHW 2008c. 2007 National Drug Strategy Household Survey: detailed findings. Drug statistics series no. 22. Cat. no. PHE 107. Canberra: AIHW.
- AIHW 2009a. Australian hospital statistics 2007–08. Health services series no. 33. Cat. no. HSE 71. Canberra: AIHW.
- AIHW 2009b. National Opioid Pharmacotherapy Statistics Annual Data collection: 2008 report. Bulletin no. 72. Cat. no. AUS 115. Canberra: AIHW.
- AIHW 2009c. Enhancing the Alcohol and Other Drug Treatment Services National Minimum Data Set: counting clients and reporting comorbidity. Bulletin no. 69. Cat. no. AUS 112. Canberra: AIHW
- AIHW: Grant B & Petrie M 2001. Alcohol and other drug treatment services: development of a national minimum data set. Cat. no. HSE 12. Canberra: AIHW.
- Bacon, V 2007. What potential might narrative therapy have to assist Indigenous Australians reduce substance misuse? *Australian Aboriginal Studies* no. 1:71–82.
- Begg S, Vos T, Barker B, Stevenson C, Stanley L & Lopez A 2007. The burden of disease and injury in Australia 2003. Cat. no. PHE 82. Canberra: AIHW.
- Dale A & Marsh A 2000. Evidence based practice indicators for alcohol and other drug interventions. Literature Review. Best practice in alcohol and other drug interventions working group. Viewed 10 April 08, <<http://www.wa.gov.au/drugwestaus/>>.

- Flannery M & Farrell M 2007. Harm reduction the key to managing problem drug users. *Practitioner* 251(1694):99, 101–6.
- HDSC (Health Data Standards Committee) 2006. National health data dictionary. Version 13. Cat. No. HWI 88. Canberra: AIHW.
- Kleber H, Weiss R, Anton RF & George T 2007. *The American Journal of Psychiatry* 164(4).
- NHMRC (National Health and Medical Research Council) 2001. Australian alcohol guidelines: health risks and benefits. Canberra: Commonwealth of Australia.
- NHMRC (National Health and Medical Research Centre) 2009. Australian guidelines to reduce health risks from drinking alcohol. Canberra: Australian Government.
- NSW Department of Health 2007. Drug and alcohol treatment guidelines for residential settings. Viewed 4 April 2008, <[www.nada.org.au/downloads/drug\\_alcohol\\_guidelines.pdf](http://www.nada.org.au/downloads/drug_alcohol_guidelines.pdf)>.
- Shand F, Gates J, Fawcett J & Mattick R 2003. The treatment of alcohol problems. A review of the evidence. Viewed 4 April 08, <[http://www.alcohol.gov.au/internet/alcohol/publishing.nsf/Content/1980DFD151B3287FCA257261000E0955/\\$File/alcproblems.pdf](http://www.alcohol.gov.au/internet/alcohol/publishing.nsf/Content/1980DFD151B3287FCA257261000E0955/$File/alcproblems.pdf)>.
- Vanderplasschen W, Wolf J, Rapp R & Broekhart E 2007. Effectiveness of different models of case management for substance-abusing populations. *Journal of Psychoactive Drugs* 39(1).
- Wilson R & Kolander C 2003. Drug abuse prevention: A school and community partnership. 2nd edn. London: Jones & Bartlett.

# List of tables

Table 2.1:	Treatment agencies by sector of service and jurisdiction, 2007–08 .....	5
Table 2.2:	Treatment agencies by geographical location and jurisdiction, 2007–08.....	6
Table 2.3:	Main treatment type by geographical location, 2007–08 (per cent).....	7
Table 3.1:	Client type by jurisdiction, 2007–08 (per cent) .....	9
Table 3.2:	Sex by age group, 2007–08 (per cent).....	9
Table 3.3:	Age group by Indigenous status and sex, 2007–08.....	10
Table 3.4:	Estimated number of ‘episodes of care’ provided by Australian Government-funded Aboriginal and Torres Strait Islander substance use-specific services (DASR) by sex, and treatment type, 2007–08 .....	12
Table 4.2:	Trends in principal drug of concern, 2001–02 to 2007–08.....	16
Table 4.3:	Principal drug of concern by jurisdiction, 2007–08 (per cent).....	18
Table 4.4:	Principal drug of concern by Indigenous status, 2007–08 .....	20
Table 4.5:	Trends in principal drug of concern by Indigenous status, 2005–06 to 2007–08 (per cent).....	21
Table 5.1:	Trends in main treatment type, 2001–02 to 2007–08.....	37
Table 5.2:	Main treatment type by jurisdiction, 2007–08 .....	39
Table 5.3:	Main treatment type by Indigenous status, 2007–08.....	40
Table 5.4:	Main treatment type, with or without additional treatment types, Australia, 2007–08 .....	41
Table 5.5:	Estimated number of pharmacotherapy clients by pharmacotherapy drug type and jurisdiction, on a ‘snapshot/specified’ day, 2008.....	52
Table 6.1:	Not stated /missing/unknown responses for data items, by jurisdiction, 2007–08 (per cent).....	55
Table 7.1:	Age group trends, 2001–02 to 2007–08.....	56
Table 7.2:	Cessation reasons grouped by indicative outcome type .....	59
Table A1.1:	Data elements for the AODTS–NMDS, 2007–08 .....	61
Table A3.1:	Client data items by jurisdiction, 2007–08 .....	65
Table A3.2:	Client data items by geographical location, 2007–08.....	67
Table A3.3:	Drug-related data items by jurisdiction, 2007–08 .....	69
Table A3.4:	Other drugs of concern by jurisdiction, 2007–08 .....	71
Table A3.5:	Principal drug of concern by geographical location, 2007–08 (per cent) .....	72
Table A3.6:	Principal drug of concern by age group, 2007–08 (per cent).....	73
Table A3.7:	Principal drug of concern and all drugs of concern, 2007–08 .....	74
Table A3.8:	Selected data items by principal drug of concern, 2007–08 (per cent).....	75
Table A3.9:	Selected drug-related data items by principal drug of concern, 2007–08 (per cent) .....	77
Table A3.10:	Principal drug of concern, with or without other drugs of concern, 2007–08 .....	78
Table A3.11:	Other drugs of concern nominated for selected principal drugs of concern, 2007–08 .....	79

Table A3.12:	Selected treatment data items by principal drug of concern, 2007–08 (per cent) .....	80
Table A3.13:	Main treatment type by principal drug of concern, clients aged 10–19 years of age, 2007–08 (per cent).....	82
Table A3.14:	Median duration in days of closed treatment episodes by principal drugs of concern, 2007–08.....	83
Table A3.15:	Selected age groups by principal drug of concern, 2007–08 (per cent).....	84
Table A3.16:	Treatment where amphetamines were the principal drug of concern by usual method of use, 2001–02 to 2007–08 .....	85
Table A3.17:	Selected treatment data items by jurisdiction, 2007–08 .....	86
Table A3.18:	Other treatment type by jurisdiction, 2007–08 .....	87
Table A3.19:	Selected client data items by main treatment type, 2007–08 .....	88
Table A3.20:	Selected treatment items by main treatment type, 2007–08 (per cent).....	90
Table A3.21:	Selected age groups by main treatment type, 2007–08 (per cent).....	92
Table A3.22:	Median duration in days of closed treatment episodes by main treatment type, 2007–08 .....	93
Table A3.23:	Principal drug of concern by main treatment type, 2007–08 (per cent).....	94
Table A3.24:	Principal drug of concern by main treatment type, clients aged 10–19 years of age, 2007–08 (per cent).....	95
Table A6.1:	Estimated number of clients seen by Australian Government-funded Aboriginal and Torres Strait Islander substance use-specific services (DASR) by jurisdiction and Indigenous status, 2007–08.....	105
Table A6.2:	Substances/ drugs for which treatment/ assistance was provided by Australian Government-funded Aboriginal and Torres Strait Islander substance use-specific services, 2007–08.....	106
Table A6.3:	Substances/ drugs for which Australian Government-funded Aboriginal and Torres Strait Islander primary health care services cover substance use issues on an individual basis as they arise, 2006–07 .....	107
Table A7.1:	Mapping of ICD-10-AM codes to ASCDC output categories .....	108

# List of figures

Figure 4.1: Selected principal drug of concern by age group, 2007-08 ..... 19  
Figure 4.2: Principal drug of concern and all drugs of concern, 2007-08 ..... 22

# List of boxes

Box 3.1: Key definition and counts for closed treatment episodes, 2007-08..... 8  
Box 4.1: Key definitions and counts for closed treatment episodes and drugs, 2007-08..... 15  
Box 5.1: Key definitions and counts for treatment programs, 2007-08 ..... 36  
Box A6.1: Comparison of treatment episode definitions in the SAR, DASR and  
AODTS-NMDS ..... 105